Zobrazeno 1 - 10 of 143 pro vyhledávání: '"C. K. Osborne"'
1
Root recovery rates forPhytophthora cinnamomiand rate of symptom development from root rot onAbies fraseritrees over 7 years
Autor: C. K. Osborne, G. J. Griffin, D. Reaver, M. M. Yancey
Publikováno v: Forest Pathology. 39:15-27
Summary Phytophthora root rot on Abies fraseri trees was monitored from 2001 to 2007 within the disease front of a 12-year-old Virginia plantation where trees had been dying of the disease since 1994. After a slow increase in early foliage symptom de
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f34a0a83af5371e57bc2c29e3dda882
https://doi.org/10.1111/j.1439-0329.2008.00555.x
Zobrazit plný text záznamu
2
Phase III Study of Standard Combination Versus Rotating Regimen of Induction Chemotherapy in Patients With Hormone Insensitive Metastatic Breast Cancer
Autor: Douglass C. Tormey, C K Osborne, Geoffrey Falkson, Kishan J. Pandya, Hu P
Publikováno v: American Journal of Clinical Oncology. 30:113-125
OBJECTIVE The objective of this multicenter phase III trial was to study the impact on time to treatment failure (TTF) and survival of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) versus CAF/thiotepa, Adriamycin, vinblastine, and Halotestin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2925bdb2dd2ec7e1f5d7f6351633e9ee
https://doi.org/10.1097/01.coc.0000251244.60473.c5
Zobrazit plný text záznamu
3
Postmenopausal Women who Progress on Fulvestrant ('Faslodex') Remain Sensitive to Further Endocrine Therapy
Autor: G Burton, Ignace Vergote, Ulrich R. Kleeberg, John F.R. Robertson, C K Osborne, L. Mauriac
Publikováno v: Breast Cancer Research and Treatment. 79:207-211
Purpose. This retrospective evaluation of data from two randomized, multicenter trials examined whether tumor responses to further endocrine therapy were seen in postmenopausal women with advanced breast cancer who had progressed on both initial endo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509ab1ca14189f2333365b3688d7c8f0
https://doi.org/10.1023/a:1023983032625
Zobrazit plný text záznamu
4
Tamoxifen-Bound Estrogen Receptor (ER) Strongly Interacts with the Nuclear Matrix Protein HET/SAF-B, a Novel Inhibitor of ER-Mediated Transactivation
Autor: Michaelis M, Zhang Q, Davie, Steffi Oesterreich, Zhao Hh, C K Osborne, Suzanne A. W. Fuqua, Torsten A. Hopp, Adrian V. Lee
Publikováno v: Molecular Endocrinology. 14:369-381
The estrogen receptor (ER) is a ligand-dependent transcription factor that acts in a cell- and promoter-specific manner. Evidence suggests that the activity of the ER can be regulated by a number of other stimuli (e.g. growth factors) and that the ef
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75674a315cb07a04892eff3ad5e5aac1
https://doi.org/10.1210/mend.14.3.0432
Zobrazit plný text záznamu
5
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer
Autor: C K Osborne
Publikováno v: Endocrine-related cancer. :271-276
Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025f438de969bc716dff836438076ec4
https://doi.org/10.1677/erc.0.0060271
Zobrazit plný text záznamu
6
Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo
Autor: Ester Coronado-Heinsohn, Jennifer L. Gooch, Adrian V. Lee, Douglas Yee, C K Osborne, Susan G. Hilsenbeck, James G. Jackson
Publikováno v: Molecular Endocrinology. 13:787-796
Cross-talk between insulin-like growth factor (IGF)- and estrogen receptor (ER)-signaling pathways results in synergistic growth. We show here that estrogen enhances IGF signaling by inducing expression of three key IGF-regulatory molecules, the type
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9573b7041c62b11fb4e3c313d8c4ece1
https://doi.org/10.1210/mend.13.5.0274
Zobrazit plný text záznamu
9
Time-dependence of hazard ratios for prognostic factors in primary breast cancer
Autor: C. De Moor, Peter M. Ravdin, Gary M. Clark, C K Osborne, Susan G. Hilsenbeck, Gary C. Chamness
Publikováno v: Breast Cancer Research and Treatment. 52:227-237
Some prognostic factors, such as steroid receptors, appear strongly related to outcome in early studies with short follow-up, but as follow-up matures the relationships appear to weaken. We investigated this phenomenon for several factors (tumor size
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b93759fbc673fd7ef016c763a315697
https://doi.org/10.1023/a:1006133418245
Zobrazit plný text záznamu
10
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study
Autor: Thomas J. Smith, Nicholas J. Robert, David Cella, M L Citron, I C Henderson, Kishan J. Pandya, M Grove-Conrad, Martin D. Abeloff, John H. Fetting, Diane L. Fairclough, C K Osborne, Richard Gray, K A Margolin
Publikováno v: Journal of Clinical Oncology. 16:2382-2391
PURPOSE The Intergroup conducted this breast cancer adjuvant trial to compare an investigational 16-week regimen with cyclophosphamide, doxorubicin, and fluorouracil (5-FU; CAF). The 16-week regimen features greater doxorubicin and 5-FU dose-intensit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccf70d430ee29e6db4077fa45131d7cb
https://doi.org/10.1200/jco.1998.16.7.2382
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje